Ocugen Inc OCGN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 8:46 AM EDT
1.47quote price arrow up+0.03 (+2.07%)
Volume
105,988
Close
1.44quote price arrow down-0.15 (-9.43%)
Volume
7,078,144
52 week range
0.34 - 2.11
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.44
  • 52 Week High2.11
  • 52 Week High Date03/25/24
  • 52 Week Low0.34
  • 52 Week Low Date10/26/23

Key Stats

  • Market Cap369.504M
  • Shares Out256.60M
  • 10 Day Average Volume9.66M
  • Dividend-
  • Dividend Yield-
  • Beta3.46
  • YTD % Change150.43

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.44
  • 52 Week High2.11
  • 52 Week High Date03/25/24
  • 52 Week Low0.34
  • 52 Week Low Date10/26/23
  • Market Cap369.504M
  • Shares Out256.60M
  • 10 Day Average Volume9.66M
  • Dividend-
  • Dividend Yield-
  • Beta3.46
  • YTD % Change150.43

RATIOS/PROFITABILITY

  • EPS (TTM)-0.26
  • P/E (TTM)-5.50
  • Fwd P/E (NTM)-5.33
  • EBITDA (TTM)-80.36M
  • ROE (TTM)-98.28%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-58,552.65%
  • Debt To Equity (MRQ)4.75%

EVENTS

  • Earnings Date05/03/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Ocugen Inc

 

Profile

MORE
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. The Company's technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. It is developing COVAXIN, which is a whole-virion inactivated intramuscular COVID-19 vaccine...
Shankar Musunuri Ph.D.
Chairman of the Board, Chief Executive Officer
Michael Breininger
Principal Financial Officer, Interim Chief Accounting Officer
Address
11 GREAT VALLEY PARKWAY
Malvern, PA
19355
United States

Top Peers

SYMBOLLASTCHG%CHG
OCS
Oculis Holding AG
11.90-0.10-0.83%
STTK
Shattuck Labs Inc
10.02+1.04+11.58%
REPL
Replimune Group Inc
7.21+0.06+0.84%
LRMR
Larimar Therapeutics Inc
7.05-0.19-2.62%
CRBP
Corbus Pharmaceuticals Holdings Inc
37.16-3.96-9.63%